Cubist Systematic Strategies LLC Grows Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Cubist Systematic Strategies LLC lifted its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 422.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 43,239 shares of the company's stock after buying an additional 34,970 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.17% of Eton Pharmaceuticals worth $576,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ETON. Baader Bank Aktiengesellschaft purchased a new position in shares of Eton Pharmaceuticals in the fourth quarter worth about $373,000. Anchor Capital Advisors LLC purchased a new position in shares of Eton Pharmaceuticals in the fourth quarter worth about $805,000. Raymond James Financial Inc. purchased a new position in shares of Eton Pharmaceuticals in the fourth quarter worth about $147,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Eton Pharmaceuticals by 230.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company's stock worth $2,862,000 after buying an additional 149,864 shares during the period. Finally, Thompson Siegel & Walmsley LLC increased its holdings in Eton Pharmaceuticals by 11.3% during the 4th quarter. Thompson Siegel & Walmsley LLC now owns 128,039 shares of the company's stock valued at $1,705,000 after purchasing an additional 13,009 shares during the period. Hedge funds and other institutional investors own 27.86% of the company's stock.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock opened at $19.70 on Friday. The stock's 50 day simple moving average is $14.72 and its two-hundred day simple moving average is $13.82. The stock has a market cap of $528.31 million, a price-to-earnings ratio of -89.55 and a beta of 1.22. Eton Pharmaceuticals, Inc. has a fifty-two week low of $3.18 and a fifty-two week high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.02). The firm had revenue of $17.28 million for the quarter, compared to the consensus estimate of $14.33 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. On average, analysts predict that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ETON shares. HC Wainwright restated a "buy" rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Craig Hallum boosted their price target on Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a "buy" rating in a report on Wednesday. Finally, B. Riley restated a "buy" rating and set a $24.00 price target (up previously from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

Want to see what other hedge funds are holding ETON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.